🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Osthole ameliorates cognitive impairment in ovariectomized rats via estrogen-mediated enhancement of cholinergic function and regulation of neurotransmitter homeostasis.

PMID: 41391505 · DOI: 10.1016/j.neuropharm.2025.110806 · Neuropharmacology, 2026 · Yanman Liu, Jimei Zhang, Wenjuan Li, Qingwen Qu, Zhengxing Shan, Chunwei Liu, Ke Jiao, Xueqin Hou
📄 Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive dysfunction that is closely associated with cholinergic system damage. Estrogen deficiency is a well-established risk factor for AD in women. Osthole (OST), a phytoestrogen with mild, bidirectional regulatory properties, has been proposed as a potential estrogen replacement. This study aimed to investigate the mechanisms by which OST ameliorates cognitive impairment. Cognitive deficits were induced in female Sprague-Dawley rats by bilateral ovariectomy (OVX), and OST was subsequently administered by oral gavage. Behavioral tests revealed that OST significantly improved learning and memory and reduced anxiety-like and depression-like behaviors in OVX rats. H&E staining and Nissl staining demonstrated that OST reversed neuronal damage in the hippocampus and cortex. Western blotting, ELISA, and immunofluorescence staining indicated that OST treatment restored the estrogen-cholinergic-NGF axis: E

Confidence: 0.32 · 9 полей извлечено
Идентификация (6 полей)
Target
—
0.00
Alt. target
—
0.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Osthole administered by oral gavage to ovariectomized rats
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Ovariectomized female Sprague-Dawley rats
0.90
Diet/model
Ovariectomy-induced estrogen deficiency
0.90
Клиника (11 полей)
Drug
Osthole
1.00
Indication
Alzheimer's disease
0.90
Patient subgroups
Postmenopausal women with estrogen deficiency
0.80
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
Preclinical
0.90
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
Improved learning and memory, reduced anxiety-like and depression-like behaviors, reversed neuronal damage
0.90
Approved
False
0.90